News and CommentScience and Commerce

'Fountain of Youth' Lifts Biotech Stock

+ See all authors and affiliations

Science  23 Jan 1998:
Vol. 279, Issue 5350, pp. 472
DOI: 10.1126/science.279.5350.472a

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

On Tuesday, 13 January, the price of shares in Geron Corp., a California-based biotech company, rose 44% after news leaked that scientists there and at the University of Texas Southwestern Medical Center had managed to stem the aging process in cultured human cells. By week's end, however, as it became clear that income-generating products of the research are distant, Geron's share price had glided back down. The research, which confirmed that the enzyme telomerase can affect cellular aging, was published in the 16 January issue of Science.

Related Content